SLDB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
57.4M
+0.1%
57.3M
+16.0%
49.4M
+2.8%
48.1M
+15.3%
41.7M
R&D
44.3M
-4.1%
46.1M
+21.0%
38.1M
-1.9%
38.9M
+19.9%
32.4M
SG&A
13.1M
+17.5%
11.2M
-0.9%
11.3M
+22.5%
9.2M
-0.9%
9.3M
Operating Income
-57384000
-0.1%
-57308000
-16.0%
-49403000
-2.8%
-48058000
-15.3%
-41693000
EBITDA
-56993000
-0.1%
-56913000
-16.3%
-48936000
-2.6%
-47682000
-15.4%
-41307000
Net Income
-54799000
+3.4%
-56737000
-14.0%
-49787000
-8.8%
-45776000
-15.9%
-39480000
EPS (Basic)
$-0.38
+26.9%
$-0.52
+0.0%
$-0.52
-8.3%
$-0.48
-14.3%
$-0.42
EPS (Diluted)
$-0.38
+26.9%
$-0.52
+0.0%
$-0.52
-8.3%
$-0.48
-14.3%
$-0.42
Shares (Diluted)
143.7M
+30.9%
109.8M
+15.4%
95.1M
+0.7%
94.4M
+0.3%
94.1M
Solid Biosciences (SLDB) โ€” Financials